

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

February 25, 2013

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We are please to inform you that the Company has received final approval from the USFDA to market Ranitidine Hcl injection 25 mg/ml.

We enclose herewith a copy of press release dated February 25, 2013 under the title **“Zydus receives final approval for Ranitidine Hcl injection”** to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH

Company Secretary

Encl.: As above.

Zydus receives final approval for Ranitidine Hcl injection

Ahmedabad, 25 February 2013

Zydus Cadila has received the final approval from the USFDA to market Ranitidine Hcl injection 25 mg/ml. Used in the treatment of peptic ulcers, gastritis and gastroesophageal reflux disease (GERD), Ranitidine Hcl falls in the anti- secretory segment.

The estimated sales in 2012 as per IMS for Ranitidine Hcl injection was USD 5.4 million.

The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.
